Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

First Posted Date: 2004-04-28

Last Posted Date: 2013-07-10

Lead Sponsor: Northwestern University

Target Recruit Count: 30

Registration Number: NCT00004174

Locations: 🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

Phase 2

Conditions: Multiple Myeloma and Plasma Cell Neoplasm

First Posted Date: 2004-04-28

Last Posted Date: 2014-01-06

Lead Sponsor: Robert H. Lurie Cancer Center

Registration Number: NCT00004903

Locations: 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸
Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic Syndromes

First Posted Date: 2004-04-28

Last Posted Date: 2014-05-02

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 36

Registration Number: NCT00003960

Locations: 🇺🇸
Johns Hopkins Oncology Center, Baltimore, Maryland, United States
🇺🇸
Center for Cancer Treatment and Research, Columbia, South Carolina, United States

Combination Chemotherapy in Treating Children With Very High Risk Acute Lymphocytic Leukemia

Phase 2

Completed

Conditions: Leukemia

Interventions: Biological: filgrastim
Drug: asparaginase
Drug: cyclophosphamide
Drug: cytarabine
Drug: daunorubicin hydrochloride
Drug: dexamethasone
Drug: etoposide
Drug: idarubicin
Drug: leucovorin calcium
Drug: mercaptopurine
Drug: methotrexate
Drug: prednisone
Drug: vincristine sulfate
Radiation: radiation therapy

First Posted Date: 2004-04-27

Last Posted Date: 2014-07-28

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 36

Registration Number: NCT00003783

Locations: 🇺🇸
West Virginia University Medical School, Charleston Division, Charleston, West Virginia, United States
🇺🇸
Simmons Cancer Center - Dallas, Dallas, Texas, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States

and more 55 locations

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Myelodysplastic Syndromes
Multiple Myeloma and Plasma Cell Neoplasm
Graft Versus Host Disease
Leukemia
Lymphoma

Interventions: Biological: anti-thymocyte globulin
Biological: filgrastim
Drug: busulfan
Drug: cyclophosphamide
Drug: cyclosporine
Drug: methylprednisolone
Procedure: bone marrow ablation with stem cell support
Procedure: umbilical cord blood transplantation
Radiation: radiation therapy

First Posted Date: 2004-04-27

Last Posted Date: 2019-12-13

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00003270

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Phase 4

Completed

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Graft Versus Host Disease
Lymphoma
Anemia
Leukemia
Myelodysplastic Syndromes

First Posted Date: 2004-04-27

Last Posted Date: 2019-10-17

Lead Sponsor: University of Maryland, Baltimore

Target Recruit Count: 45

Registration Number: NCT00003398

Locations: 🇺🇸
Marlene & Stewart Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland, United States

Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer

Phase 2

Completed

Conditions: Kidney Cancer
Sarcoma

First Posted Date: 2004-04-26

Last Posted Date: 2013-06-20

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Registration Number: NCT00002466

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer

Phase 2

Completed

Conditions: Leukemia
Lymphoma

First Posted Date: 2004-04-26

Last Posted Date: 2011-11-30

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 50

Registration Number: NCT00002553

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

First Posted Date: 2004-04-23

Last Posted Date: 2016-10-04

Lead Sponsor: Fred Hutchinson Cancer Center

Registration Number: NCT00003899

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Vaccine Therapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer

Phase 2

Terminated

Conditions: Ovarian Cancer

First Posted Date: 2004-04-23

Last Posted Date: 2013-04-11

Lead Sponsor: Gynecologic Oncology Group

Registration Number: NCT00003386

Locations: 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸
CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸
Rush-Presbyterian-St. Luke's Medical Center, Chicago, Illinois, United States

and more 57 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy